{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:20:01Z","timestamp":1778631601680,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 AI054564"],"award-info":[{"award-number":["P01 AI054564"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P51 OD011092"],"award-info":[{"award-number":["P51 OD011092"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 AI087064"],"award-info":[{"award-number":["P01 AI087064"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HD058304"],"award-info":[{"award-number":["HD058304"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5 T32 AI7472-17"],"award-info":[{"award-number":["5 T32 AI7472-17"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.vaccine.2012.06.042","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T17:39:39Z","timestamp":1340818779000},"page":"5519-5526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially"],"prefix":"10.1016","volume":"30","author":[{"given":"Franco","family":"Pissani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine C.","family":"Malherbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harlan","family":"Robins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor R.","family":"DeFilippis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Sellhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonidas","family":"Stamatatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Overbaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy L.","family":"Haigwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2012.06.042_bib0005","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2010.09.011","article-title":"Induction of immunity to human immunodeficiency virus type-1 by vaccination","volume":"33","author":"McElrath","year":"2010","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.vaccine.2012.06.042_bib0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00063030-200923030-00001","article-title":"Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1)","volume":"23","author":"Vaine","year":"2009","journal-title":"BioDrugs"},{"issue":"8","key":"10.1016\/j.vaccine.2012.06.042_bib0015","doi-asserted-by":"crossref","first-page":"e12076","DOI":"10.1371\/journal.pone.0012076","article-title":"Comparative immunogenicity of HIV-1 clade C envelope proteins for prime\/boost studies","volume":"5","author":"Smith","year":"2010","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.vaccine.2012.06.042_bib0020","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1128\/JVI.00081-11","article-title":"Two closely related env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates","volume":"85","author":"Vaine","year":"2011","journal-title":"J Virol"},{"issue":"October (19)","key":"10.1016\/j.vaccine.2012.06.042_bib0025","doi-asserted-by":"crossref","first-page":"9887","DOI":"10.1128\/JVI.05086-11","article-title":"Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA","volume":"85","author":"Zolla-Pazner","year":"2011","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2012.06.042_bib0030","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1128\/JVI.00389-08","article-title":"Characterization of neutralizing antibody responses elicited by clade a envelope immunogens derived from early transmitted viruses","volume":"82","author":"Kraft","year":"2008","journal-title":"J Virol"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.06.042_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/COH.0b013e32834e0667","article-title":"Systems biology in understanding HIV pathogenesis and guiding vaccine development","volume":"7","author":"Sekaly","year":"2012","journal-title":"Curr Opin HIV AIDS"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.06.042_bib0040","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/icb.2010.65","article-title":"Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses","volume":"89","author":"Sirskyj","year":"2011","journal-title":"Immunol Cell Biol"},{"issue":"June (2)","key":"10.1016\/j.vaccine.2012.06.042_bib0045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.virol.2010.03.007","article-title":"An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120","volume":"401","author":"Moseri","year":"2010","journal-title":"Virology"},{"issue":"81","key":"10.1016\/j.vaccine.2012.06.042_bib0050","doi-asserted-by":"crossref","first-page":"81ra36","DOI":"10.1126\/scitranslmed.3002351","article-title":"Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys","volume":"3","author":"Letvin","year":"2011","journal-title":"Science Translational Medicine"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2012.06.042_bib0055","doi-asserted-by":"crossref","first-page":"9092","DOI":"10.1128\/JVI.72.11.9092-9100.1998","article-title":"Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting","volume":"72","author":"Richmond","year":"1998","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2012.06.042_bib0060","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1084\/jem.20100025","article-title":"Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates","volume":"207","author":"Sundling","year":"2010","journal-title":"J Exp Med"},{"issue":"April (17)","key":"10.1016\/j.vaccine.2012.06.042_bib0065","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1016\/j.vaccine.2010.02.006","article-title":"Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity","volume":"28","author":"Vaine","year":"2010","journal-title":"Vaccine"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2012.06.042_bib0070","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1128\/JVI.02036-08","article-title":"Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection","volume":"83","author":"Sather","year":"2009","journal-title":"J Virol"},{"issue":"July (14)","key":"10.1016\/j.vaccine.2012.06.042_bib0075","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1128\/JVI.00110-09","article-title":"Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm","volume":"83","author":"Simek","year":"2009","journal-title":"J Virol"},{"issue":"June (12)","key":"10.1016\/j.vaccine.2012.06.042_bib0080","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1128\/JVI.00239-07","article-title":"Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection","volume":"81","author":"Gray","year":"2007","journal-title":"J Virol"},{"issue":"October (19)","key":"10.1016\/j.vaccine.2012.06.042_bib0085","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1128\/JVI.01149-09","article-title":"Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression","volume":"83","author":"Piantadosi","year":"2009","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2012.06.042_bib0090","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1046-2023(03)00135-X","article-title":"DNA vaccine strategies: candidates for immune modulation and immunization regimens","volume":"31","author":"Doria-Rose","year":"2003","journal-title":"Methods"},{"issue":"May (21)","key":"10.1016\/j.vaccine.2012.06.042_bib0095","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1016\/j.vaccine.2005.08.023","article-title":"Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine","volume":"24","author":"Wang","year":"2006","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2012.06.042_bib0100","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.biotechadv.2009.02.003","article-title":"Plasmid DNA vaccine vector design: Impact on efficacy, safety and upstream production","volume":"27","author":"Williams","year":"2009","journal-title":"Biotech Adv"},{"issue":"November (22)","key":"10.1016\/j.vaccine.2012.06.042_bib0105","doi-asserted-by":"crossref","first-page":"10991","DOI":"10.1128\/JVI.75.22.10991-11001.2001","article-title":"Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein","volume":"75","author":"Deml","year":"2001","journal-title":"J Virol"},{"issue":"June (12)","key":"10.1016\/j.vaccine.2012.06.042_bib0110","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1128\/JVI.75.12.5526-5540.2001","article-title":"The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region","volume":"75","author":"Barnett","year":"2001","journal-title":"J Virol"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2012.06.042_bib0115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/088922204323048177","article-title":"Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles","volume":"20","author":"Mossman","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"9","key":"10.1016\/j.vaccine.2012.06.042_bib0120","doi-asserted-by":"crossref","first-page":"e3214","DOI":"10.1371\/journal.pone.0003214","article-title":"A recoding method to improve the humoral immune response to an HIV DNA vaccine","volume":"3","author":"Huang","year":"2008","journal-title":"PloS One"},{"issue":"November (21)","key":"10.1016\/j.vaccine.2012.06.042_bib0125","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1128\/JVI.77.21.11563-11577.2003","article-title":"Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge","volume":"77","author":"Doria-Rose","year":"2003","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2012.06.042_bib0130","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/COH.0b013e32833d2d45","article-title":"Strategies for eliciting HIV-1 inhibitory antibodies","volume":"5","author":"Tomaras","year":"2010","journal-title":"Current Opinion in HIV and AIDS"},{"issue":"June (11)","key":"10.1016\/j.vaccine.2012.06.042_bib0135","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1128\/JVI.02419-10","article-title":"Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies","volume":"85","author":"Malherbe","year":"2011","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2012.06.042_bib0140","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.virol.2009.11.032","article-title":"Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response","volume":"398","author":"Bosch","year":"2010","journal-title":"Virology"},{"issue":"December (24)","key":"10.1016\/j.vaccine.2012.06.042_bib0145","doi-asserted-by":"crossref","first-page":"8370","DOI":"10.1128\/JB.187.24.8370-8374.2005","article-title":"A relative-entropy algorithm for genomic fingerprinting captures host-phage similarities","volume":"187","author":"Robins","year":"2005","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2012.06.042_bib0150","article-title":"Detecting signatures of selection from DNA sequences using Datamonkey","volume":"537","author":"Poon","year":"2009"},{"key":"10.1016\/j.vaccine.2012.06.042_bib0155","article-title":"Selecton 2007: advanced models for detecting positive and purifying selection using a Bayesian inference approach","volume":"July (35)","author":"Stern","year":"2007","journal-title":"Nucleic Acids Res"},{"issue":"May (1)","key":"10.1016\/j.vaccine.2012.06.042_bib0160","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/genetics\/155.1.431","article-title":"Codon-substitution models for heterogeneous selection pressure at amino acid sites","volume":"155","author":"Yang","year":"2000","journal-title":"Genetics"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.06.042_bib0165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/oxfordjournals.molbev.a004233","article-title":"Pervasive adaptive evolution in mammalian fertilization proteins","volume":"20","author":"Swanson","year":"2003","journal-title":"Molecular Biology and Evolution"},{"issue":"5","key":"10.1016\/j.vaccine.2012.06.042_bib0170","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2144\/000113370","article-title":"DIVEIN: a web server to analyze phylogenies, sequence divergence, diversity, and informative sites","volume":"48","author":"Deng","year":"2010","journal-title":"BioTechniques"},{"issue":"October (20)","key":"10.1016\/j.vaccine.2012.06.042_bib0175","doi-asserted-by":"crossref","first-page":"11244","DOI":"10.1128\/JVI.77.20.11244-11259.2003","article-title":"Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate","volume":"77","author":"Srivastava","year":"2003","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2012.06.042_bib0180","doi-asserted-by":"crossref","first-page":"e10254","DOI":"10.1371\/journal.pone.0010254","article-title":"Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes","volume":"5","author":"Nixon","year":"2010","journal-title":"PLoS One"},{"issue":"51","key":"10.1016\/j.vaccine.2012.06.042_bib0185","doi-asserted-by":"crossref","first-page":"18514","DOI":"10.1073\/pnas.0504658102","article-title":"Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection","volume":"102","author":"Frost","year":"2005","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"5","key":"10.1016\/j.vaccine.2012.06.042_bib0190","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/COH.0b013e32832ea7e8","article-title":"Specificity of the autologous neutralizing antibody response","volume":"4","author":"Moore","year":"2009","journal-title":"Current Opinion in HIV and AIDS"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2012.06.042_bib0195","doi-asserted-by":"crossref","first-page":"e1000598","DOI":"10.1371\/journal.ppat.1000598","article-title":"Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection","volume":"5","author":"Moore","year":"2009","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.vaccine.2012.06.042_bib0200","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.virol.2009.11.009","article-title":"Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity","volume":"397","author":"Bunnik","year":"2010","journal-title":"Virology"},{"issue":"16","key":"10.1016\/j.vaccine.2012.06.042_bib0205","doi-asserted-by":"crossref","first-page":"7932","DOI":"10.1128\/JVI.00757-08","article-title":"Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection","volume":"82","author":"Bunnik","year":"2008","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2012.06.042_bib0210","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1128\/JVI.02622-09","article-title":"Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors","volume":"84","author":"van Gils","year":"2010","journal-title":"J Virol"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2012.06.042_bib0215","doi-asserted-by":"crossref","first-page":"e1000594","DOI":"10.1371\/journal.ppat.1000594","article-title":"Escape from autologous neutralizing antibodies in acute\/early subtype C HIV-1 infection requires multiple pathways","volume":"5","author":"Rong","year":"2009","journal-title":"PLoS Pathog"},{"issue":"7","key":"10.1016\/j.vaccine.2012.06.042_bib0220","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1128\/JVI.02252-09","article-title":"Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs","volume":"84","author":"Nkolola","year":"2010","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12009085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12009085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:50:27Z","timestamp":1778629827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12009085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":44,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0264410X12009085"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.06.042","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.06.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}